Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
– Sell
-1,780
Closed -$234K – 1285
2025
Q2
$234K Buy
+1,780
New +$222K 0.01% 1076
2024
Q4
– Sell
-3,420
Closed -$629K – 1078
2024
Q3
$629K Sell
3,420
-110
-3% -$23K 0.02% 633
2024
Q2
$757K Sell
3,530
-14
-0.4% -$3.04K 0.02% 573
2024
Q1
$764K Buy
3,544
+48
+1% +$11.2K 0.02% 568
2023
Q4
$905K Buy
3,496
+475
+16% +$117K 0.03% 484
2023
Q3
$776K Sell
3,021
-648
-18% -$173K 0.03% 486
2023
Q2
$1.05M Sell
3,669
-601
-14% -$179K 0.04% 425
2023
Q1
$1.19M Buy
4,270
+366
+9% +$101K 0.05% 380
2022
Q4
$1.08M Sell
3,904
-145
-4% -$41K 0.05% 391
2022
Q3
$1.08M Buy
+4,049
New +$860K 0.06% 344
2021
Q1
– Sell
-2,489
Closed -$609K – 779
2020
Q4
$609K Sell
2,489
-767
-24% -$198K 0.05% 417
2020
Q3
$924K Sell
3,256
-225
-6% -$62.8K 0.08% 263
2020
Q2
$931K Buy
+3,481
New +$1.05M 0.09% 238
2019
Q1
– Sell
-968
Closed -$291K – 479
2018
Q4
$291K Buy
968
+232
+32% +$74K 0.06% 334
2018
Q3
$260K Buy
+736
New +$253K 0.04% 397

Other funds holding BIIB

Mutual Advisors's BIIB Position: Q3 2025 in Review

Mutual Advisors sold out of Biogen (BIIB) in Q3 2025, closing a stake of 1,780 shares — an estimated $234K sold.

Mutual Advisors first reported a position in BIIB in Q3 2018 and held it in 15 quarters. The position peaked at $1.19M in Q1 2023. 907 funds tracked by Wall St. Rank hold BIIB as of Q3 2025.

  • Mutual Advisors reported no remaining Biogen position as of Q3 2025 after selling out during the quarter.
  • Mutual Advisors sold 1,780 Biogen shares in Q3 2025, an estimated $234K.
  • Mutual Advisors first reported a position in Biogen in Q3 2018 and held it in 15 quarters.
  • Mutual Advisors's Biogen position peaked at $1.19M in Q1 2023.
  • 907 funds tracked by Wall St. Rank held Biogen as of Q3 2025.

Based on Mutual Advisors's 13F filing for Q3 2025, filed 4 Nov 2025.